Microsaic Systems partners with the CPI for use of MS instruments in bioprocessing

Microsaic Systems (LON:MSYS), the developer of point-of-need mass spectrometry instruments, has today announced that it has partnered with the Centre for Process Innovation, utilising the CPI’s UK biotherapeutics facility, to demonstrate the potential use of Microsaic’s MS instruments in bioprocessing.

Glenn Tracey, CEO of Microsaic, commented, “We are very pleased to be working with the CPI on this project, which brings together our combined expertise in analytical instrumentation and biologics manufacturing. Importantly, we are not aware of any other technology which can measure simultaneously small and large molecules in-situ, enabling real-time bioreactor control within a closed loop system. End-user validation, which will be available throughout the project, will be a very important mechanism for connecting us to significant end-markets.

“The biomanufacturing industry faces increasing demands from regulatory agencies, wanting better analytics to provide appropriate process monitoring and control methods during the manufacture of biologics. We believe that this MS-based intelligent solution could enable key process parameters to be determined based on real-time and historic data to satisfy these demands.

“Microsaic’s point-of-need MS solution facilitates the adoption of closed-loop control which is designed directly into the biomanufacturing process. Ongoing market and customer feedback reassures us that our offering is ahead of all others in the field, and the point-of-need differentiation utilising our proprietary miniaturised technology positions Microsaic favourably to gain traction in this new, high-growth application area.”

Starting in January 2020, the project will take approximately 12 months and will deliver an on-line, and real-time method for bioreactor chemical analysis and control. Directly interfaced with the bioreactor, Microsaic’s point-of-need MS detector will be integrated with “closed-loop” software which will control the overall system, and will provide continuous, real-time control of the biomanufacturing process, including the provision of additional data analytics for quality monitoring and assurance.

The CPI connects academia, businesses and funders to bring bright ideas and research into the marketplace.  It offers facilities across a network of sites which provide equipment and technical expertise that help companies to develop next-generation products and processes.  One such facility is the National Biologics Manufacturing Centre, a state-of-the-art facility which aims to significantly increase the UK’s manufacturing capability in biologics (medicines produced from biological sources such as proteins and DNA). The centre promotes industry collaboration across the supply chain, from research through to manufacture and commercialisation. 

Biopharmaceuticals is a well-established and rapidly growing sector (currently valued at circa $200Bn), which faces significant challenges around process robustness.  This is particularly within upstream processing, which relies on fundamental biology and carries inherent product variability. Point-of-need MS would provide timely and critical safety assurance, as adverse effects would be identified and mitigated upstream. 

The analytical instrumentation market in upstream bioprocessing alone is projected to be worth circa $390M in 2020*. The Company believes that its compact, easy-to-use, MS technology is well-positioned to access a share of this market, working with bioprocessing instrument providers and end-users in biopharmaceutical manufacturing alike.

*Report on upstream bioprocessing analytical instrumentation, TDA consultants 2019

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn

    More articles like this

    CEO Q&A with Glenn Tracey at Microsaic Systems (LON:MSYS)

    Microsaic Systems’ Glenn Tracey discusses the highlights from their final results, what the 12 OEM & distribution agreements mean to the business operationally, the benefits of the MiD ProteinID products and how the new financial year has started in this exclusive interview with DirectorsTalk.

    Microsaic Systems Delivering a good year of growth

    Microsaic Systems plc (LON:MSYS) CEO Glenn Tracey joins DirectorsTalk to discuss full year results. Glenn talks us through the highlights, with 12 OEM and distribution agreements in place what this means for the business, the benefits the

    Microsaic Systems to further strengthen capabilities in 2020

    Microsaic Systems plc (LON:MSYS), the developer of point of need mass spectrometry (“MS”) instruments, today announced its audited financial results for the year ended 31 December 2019. The Company’s Annual Report is included at the end

    Microsaic Systems appoint WH Ireland as Joint Broker

    Microsaic Systems plc (LON:MSYS), the developer of point of need mass spectrometry instruments, has today announced the appointment of WH Ireland Limited as Joint Broker with immediate effect, alongside N+1Singer as Nominated Adviser and Joint Broker.

    Microsaic Systems partner with Axcend Corp

    Microsaic Systems plc (LON:MSYS), the developer of point of need mass spectrometry instruments, today announced that it has signed a global integration and joint sales and marketing heads of terms with Axcend Corp to integrate the

    Microsaic Systems Growing pipeline of opportunities

    Microsaic Systems (LON:MSYS), the developer of point of need mass spectrometry (“MS”) instruments, has today confirmed that revenues for the year ending 31 December 2019 have significantly exceeded 2018, and increasing momentum is being achieved in

    Microsaic Systems plc

    Microsaic Systems plc Deepens collaboration with Chinese partner

    Microsaic Systems plc (LON: MSYS), the developer of point of need mass spectrometry (“MS”) instruments, announces that its Chinese partner, Unimicro Technologies Inc. (“Unimicro”), has completed further integrations of Microsaic’s technology with Unimicro’s separation technology. Glenn

    Microsaic Systems plc

    Microsaic Systems plc AGM and Posting of Annual Report

    Microsaic Systems plc (LON: MSYS), the developer of point of need mass spectrometry instruments, has today announced that its Annual General Meeting will be held at 11.00 a.m. on 14 May 2019 at the offices of N+1